Background. Papillary thyroid carcinoma has excellent survival, yet recurrence remains a challenge. We sought to determine the proportion of reoperations performed for persistent, rather than truly recurrent, disease. Methods. We conducted a retrospective review of a prospectively maintained database. Patients with papillary thyroid carcinoma who underwent reoperation for disease from 2000-2016 were included. We defined recurrence as disease that developed after a patient had an undetectable thyroglobulin and a negative ultrasonography within 1 year of operation. Results. A total of 69 patients underwent 92 reoperations. On initial pathology, mean tumor size was 2.6 cm, 51% were multifocal, and 42% had extrathyroidal extension. Half (46%) of the patients underwent a central/lateral neck dissection at the initial operation, and 77% were treated with postoperative radioactive iodine. The median time to first reoperation was 21 months (range, 1-292), and 42% occurred within 1 year. Only 3 operations met criteria for true "recurrence," while 71 operations were categorized as persistent disease. Conclusion. Many reoperations for papillary thyroid carcinoma are for management of persistent disease. More than half of the patients required reoperation within the first 2 years, which suggests strongly that improvements in the preoperative assessment and adequacy of initial operative therapy need to be made to improve the care of patients with thyroid cancer.
the adequacy of initial operative management to optimize outcomes for thyroid cancer patients.
The aim of this study was to characterize patients who underwent reoperation for PTC and to examine what percentage of reoperations are truly for "recurrent" disease versus management of persistent disease. We hypothesized that patients who had earlier reoperations likely had persistent disease and that abnormalities in Tg and ultrasound would support this classification.
Methods
We conducted a retrospective review of a prospectively maintained thyroid surgical database. All patients who underwent reoperative surgery for PTC from 2000-2016 who had the entire thyroid gland removed previously, either through a 1-stage or 2-stage procedure (ie, completion thyroidectomy) were included. Demographic variables, preoperative and postoperative imaging and laboratory results, and pathology results from both the initial operation and reoperative operations were collected and analyzed. We focused specifically on Tg levels and neck ultrasonography examinations. We recorded both stimulated and unstimulated Tg values at both preoperative and postoperative time points when available. For those who underwent postoperative treatment with radioactive iodine, we focused on posttreatment values.
We classified disease as a true "recurrence" if a patient had an undetectable Tg in the absence of Tg antibodies and a negative neck ultrasonography within 1 year of the previous operation. We defined persistent disease as having a positive Tg level, an abnormal ultrasonography, or persisting increased serum levels of Tg antibodies. Specifically, an undetectable Tg was defined as <0.2 ng/mL for unstimulated and <1.0 ng/mL for stimulated levels. 7 An ultrasonography was defined as abnormal if it included any of the following phrases: abnormal tissue in thyroid bed, abnormal or suspicious lymph nodes in the central or lateral neck, increase in growth of mass or lymph nodes, or invasion of surrounding structures. Time to recurrence was measured from the date of the most recent neck operation.
Descriptive statistics were reported as a mean with a standard deviation for continuous variables or as a frequency with a percent for nominal variables. Kaplan-Meier and Cox regression models were used to evaluate time to reoperation. All analyses were performed using SPSS 23 (IBM, Chicago, IL). The Institutional Review Board of the University of Wisconsin, Madison approved this study, and patient information was protected in accordance with the Health Insurance Portability and Accountability Act.
Results
Our cohort included 69 patients undergoing a total of 92 reoperations for PTC, with 19 patients having >1 reoperation for recurrent or persistent disease (Fig. 1) . When evaluating the initial operation, 46% (n = 32) of patients had some form of neck dissection at the same time as their initial thyroidectomy (Table I) . Most (78%) initial operations were performed at referring facilities, while 22% of initial operations were performed at our institution.
Demographics and characteristics of initial operation
The majority of patients were female (69%), and the mean age was 42 years, with 55% being <45 years of age (Table II) . Initial tumor pathology was PTC in all patients and included variants such as follicular (9%), tall cell (7%), and sclerosing (3%). On pathologic review, the average tumor size was 2.7 cm, 50% had multifocal disease, 35% had extracapsular invasions, 42% had extrathyroidal extension, and 30% reported lympho-vascular invasion. When categorized using the ATA risk stratification, 15% were in the high-risk group (n = 10), 57% in the intermediate-risk group (n = 39), 16% in the low-risk group (n = 11), and the remaining 13% (n = 9) were unable to be classified. Of the 69 patients, 77% went on to receive radioactive iodine treatment after the initial thyroid operation (Table II and  Table III ).
Time to reoperation
We examined time from initial operation to first reoperation in all 69 patients. The median time to reoperation was 21 months, with a range of 1 month to 292 months (Fig. 2) . Most reoperations (78%) occurred within the first 5 years, 53% were in the first 2 years, and 42% were within 1 year from initial operation.
Thyroglobulin and ultrasound results
We classified patients as having persistent or recurrent disease based on ultrasonography, Tg, and Tg antibodies within 1 year of the initial operation (Fig. 3) . We classified 71 reoperations (77%) as persistent disease. Of the reoperations for persistent disease, 80% had an abnormal ultrasonography, 70% had a positive Tg level, and 13% had persistently increased serum levels of Tg antibodies within 1 year of operation. Only 3 reoperations were performed for truly recurrent disease based on a strict definition of a negative Tg, no Tg antibodies, and a negative ultrasonography prior to reoperation. These patients underwent reoperation at time points of 14 months, 37 months, and 93 months after their initial operation. The mean time to recurrence in these patients was 48 months in comparison to the entire cohort, which was only 21 months. Eighteen reoperations (20%) had incomplete follow-up data and therefore could not be categorized accurately as either persistent or recurrent disease. In addition, 19 patients had multiple reoperations. A subset analysis was done including first reoperations only, and outcomes were comparable to the results above. All 3 recurrences occurred in patients at the first reoperation (n = 3). The additional 23 reoperations on these 19 patients all had either a positive Tg and/ or positive ultrasonography within 1 year after previous operation. None met our definition of a true recurrence. The median follow up time of this cohort was 24 months (1-158); 19 patients were lost to follow-up, and 6 patients died, all due to complications from metastatic PTC.
Patients with "recurrent" disease
We classified 3 patients as having true recurrence based on an undetectable Tg level and a negative neck ultrasonography within 1 year after their initial operation. Patient 1 underwent total thyroidectomy and left central neck dissection with pathology reporting 3 of 9 nodes positive for classic PTC. Postoperatively, these patients had undetectable serum levels of Tg and is negative cervical ultrasonographies at 7 months. At 13 months, a repeat ultrasonography showed left lateral neck adenopathy with fine-needle aspiration confirming nodal disease. A left lateral neck dissection was performed, and pathology reported 2 of 33 nodes positive for PTC. Patient 2 underwent total thyroidectomy with left central neck dissection with 2 of 2 nodes positive for classic PTC. Serum Tg was undetectable and ultrasonography was negative at 12 months postoperatively. Serum Tg first became increased to 0.4 ng/mL 79 months later, where ultrasonography at 84 months identified a left central neck mass. Repeat left central neck dissection was performed 93 
Discussion
Currently, all reoperations after an initial total thyroidectomy for thyroid cancer are labeled as a recurrence. We questioned whether these reoperations were labeled appropriately as a recurrence and if most reoperations are truly for management of persistence disease. While we recognize that recurrence is a major problem for patients with thyroid cancer, we were interested in determining how often a reoperation is needed in patients who achieve an optimal outcome after their initial treatment (both a negative cervical ultrasonography and undetectable serum Tg level). We examined all patients who underwent reoperative surgery for PTC and found that most patients required reoperation <24 months after their original thyroidectomy, almost half within the first year. In reviewing these cases, we could only identify 3 cases that represented a true disease recurrence after a previous time in which their neck ultrasonography was negative and their serum Tg was undetectable. We found that almost all reoperations for thyroid cancer had evidence of persistent disease at their first follow-up after their original thyroidectomy and that these reoperations were really for ongoing management of persistent disease. This observation highlights that the problem of recurrent disease in thyroid cancer, which can be best addressed by optimizing our initial evaluation and management of these patients.
Stimulated and unstimulated serum Tg levels have been available for the last several decades as markers of disease surveillance and are now utilized to determine postoperative treatment, specifically the need for radioactive iodine treatment or the need for repeat operative intervention. 11 Several studies have shown that undetectable postoperative serum Tg levels correspond with a low incidence of recurrence, while increased Tg levels are associated with recurrence. [12] [13] [14] [15] Rosario et al demonstrated that Tg levels often detected recurrent PTC, even prior to structurally detectable disease on ultrasonography. 16 One study evaluating the risk of recurrent PTC demonstrated an increase in Tg of >2-fold was seen in 80% of patients with recurrence, and only 13% of patients without recurrent PTC. 17 In our cohort, the majority of patients had persistently increased Tg levels after their original operation, suggesting that disease or at least thyroid tissue was still present after their initial treatment. While a persistently increased Tg level after thyroidectomy could represent a normal thyroid remnant, those patients are not necessarily captured in our dataset because all patients in our study subsequently had a reoperation with pathologically proven disease.
We considered persistently increased serum levels of Tg antibodies to be abnormal and interpreted them as a potential marker of persistent disease. While the presence of Tg antibodies does not necessarily equate to disease recurrence, we thought that persistently increased Tg levels could be masking persistent disease, and we thought it was safest to assume the worst case for our analysis so that we could have the cleanest definition for recurrence. The importance of a persistently increased serum level of Tg antibody after total thyroidectomy is unclear. Xu et al examined trends in Tg antibody levels after total thyroidectomy for thyroid cancer and found that Tg Ab levels resolved in the majority of patients (25/35) but took a median of 11 months postoperatively to resolve. In their cohort of patients with persistently increased Tg Ab, only one patient had to undergo a reoperation for proven disease. 18 In contrast, another group looked at recurrences in PTC and changes in serum Tg antibodies and stratified these recurrences into the following categories: persistently high and increasing Tg antibodies, persistently medium and decreasing Tg antibodies, and decreasing to negative. Patients with persistently high, increasing, and persistently medium Tg antibodies had more disease (P < .001). In addition, the trend of the changes in serum Tg antibody levels was a strong predictor of PTC disease on multivariable analysis. 19 While the presence of Tg Ab after total thyroidectomy does not necessarily correlate with persistent disease, it is expected that the levels of these TG antibodies should resolve or decrease over time. If they do not, then they likely represent persistent disease.
Cervical ultrasonography is recommended as a tool for surveillance of postoperative disease in PTC. 7 In our study, 80% of reoperations had an abnormal ultrasonography within 1 year from their previous operation. Miah et al looked at the utility of surveillance ultrasonography post-thyroidectomy and demonstrated that lymph node mapping can detect recurrent PTC when serum Tg levels are undetectable. 20 Other studies supported the usefulness of neck ultrasonography in the early diagnosis of recurrence, where one study reported a 31.5 times greater chance of recurrent disease if there were detectable abnormalities (i.e., masses, lymphadenopathy) by ultrasonography in the thyroid bed.
12,17 Ultrasonography has been advocated in the preoperative evaluation of patients prior to their initial operation, but adherence with this recommendation has been variable, and there is substantial variation in the quality of preoperative neck ultrasonographies to evaluate for lymph node involvement. 21 Missing or inadequate preoperative imaging is likely a contributing factor to persistent disease recognized in the early postoperative period. Much of the disease identified postoperatively at 6 months or 1 year after thyroidectomy was likely present at the initial operation but simply not recognized.
When examining our cohort, it is important to consider the variables that contribute to the risk of recurrence. Almost half of our patients had some sort of lymph node dissection at their initial operation. Patients with nodal disease at their initial operation have greater incidences of recurrence than those patients without lymph node involvement. 5 In addition, Poehls et al reported that positive nodal disease on preoperative ultrasonography corresponded with greater rates of repeat operation compared with those with a negative preoperative ultrasongraphy. 22 The risk of recurrence in patients with lymph node disease also is related to the number and ratio of lymph nodes involved. If patients have a large number of nodes involved or have a high lymph node ratio, (number of positive nodes/number of nodes removed) then they are at significantly greater risk of recurrence. 23, 24 While nodal recurrence can be a reflection of the initial extent of disease, it also may reflect the adequacy of the initial operative management. Beside lymph node involvement at the time of the initial operation, our cohort had other risk factors for recurrence. On initial pathology, extrathyroidal extension and lympho-vascular invasion were common, and the majority of patients were classified as intermediate or high risk for recurrence per the ATA risk stratification. These variables have been show to increase the risk of recurrence, which is applicable to our cohort. 5, 6 The most alarming finding from our data was the short interval between the initial operation and the reoperation, and the fact that most patients never achieved a disease-free state, suggesting these reoperations were not for true recurrence, but instead for persistent disease. Specifically in patients, 2 required multiple reoperations, none achieved a disease-free status after any reoperation, suggesting that it is difficult to achieve a disease-free status after the second, third, or fourth reoperation. Although there are some patient and disease risk factors that surgeons and providers cannot change (advanced disease at presentation, tumor biology, etc.), there are other areas that surgeons can influence outcomes. Specifically, the importance of a thorough, preoperative lymph node evaluation, the quality of the initial thyroidectomy, and the appropriate postoperative treatment and follow-up. Onkendi et al evaluated a cohort of patients who underwent reoperation for recurrent PTC and reported that improved surgical technique or preoperative localization might have decreased recurrence risk in 15%-20% of their cohort. Inadequate preoperative ultrasonographies in 5%, nodal recurrence in the operative field in 10%, and a combination of the 2 in 3% were cited as reasons for relapse. 25 We must ensure all lymph node compartments are assessed adequately on imaging and any abnormal appearing nodes interrogated. Central and lateral neck dissections should not only include only the grossly positive nodes but a healthy margin of normal appearing lymph tissue to ensure microscopic disease is removed. Shortterm markers, such as Tg levels and lymph node ratios, should be tracked by surgeons regularly in the postoperative period and used as tools to guide measures of quality improvement. It is important that we strive for continuous improvement in our initial operative management, in order to decrease the morbidity from reoperative surgery in these patients.
There are several limitations of this study. This was a retrospective study, and we were limited by the data that was available in the medical record for review. This inability to retrieve some data was a particular problem when trying to evaluate the cause of the persistent disease. Because most of the initial operations were performed outside our institution, it was difficult to determine the quality of preoperative staging and operative management. Because a relatively small number of patients were considered to be diseasefree after their initial operation, this assumption prevented us from doing a comparative analysis between those patients with persistent or recurrent disease. In addition, our conclusions can only be applied to patients with PTC who underwent reoperation, because our cohort did not include PTC patients who did not require a reoperation. There also may be a selection bias because many of these patients were referred to a tertiary care center, and thus the severity of their disease may be greater than the average patient with thyroid cancer. Additionally, a small subset of patients did not have all laboratory and radiography results documented or available at all examined time points, which limited our ability to classify all patients as having persistent or recurrent disease based on the results that were available. While the schedule for postoperative surveillance is standardized at our institution, a large part of our cohort was referred to our institution, and there is likely substantial variability in both the preoperative and postoperative follow-up of patients.
In summary, our examination of reoperations for PTC showed a large number of patients who underwent early reoperation due to postoperative findings on cervical ultrasonography or increased serum levels of Tg demonstrating persistent disease. Many factors may contribute to this end result, including the quality and extent of preoperative evaluation and the initial operation, and postoperative treatment with radioactive iodine. Improvements in these areas are critical to improving the care of patients with thyroid cancer, decreasing their lifetime risk of recurrence, avoiding unnecessary or unindicated radioactive iodine treatment, and preventing avoidable reoperations.
